334 women took 360 mcg MK-7 or dummy capsules for 1 year; ucOC fell; bone loss did not differ.
Trial · randomized into two groups; the abstract does not give the numbers per group · 1 year · maker-supplied
Emaus et al., 2010
Terms and sources
- 334 women
- Healthy Norwegian women aged 50–60, 1 to 5 years after menopause. The abstract does not give how many were in each group.
- 360 mcg MK-7
- As natto capsules. The dummy capsules looked the same and contained olive oil.
- ucOC fell
- Undercarboxylated osteocalcin fell and carboxylated osteocalcin rose with MK-7 compared with the dummy capsules (p < 0.001).
- bone loss did not differ
- Bone density at the total hip, femoral neck, lumbar spine and whole body after 12 months did not differ significantly. Blood markers of bone formation and breakdown were measured; the abstract reports no difference for them.
- maker-supplied
- Grants from the Norwegian Osteoporosis Association and Northern Norway Regional Health Authorities. NATURAL provided the study capsules. Eckboe's legacy paid for blood analyses.
Study · Abstract only · about 2 min to read
Abstract only. Our estimate at about 200 words a minute, from the PubMed abstract.
Study summary
334 healthy Norwegian women aged 50 to 60 took part, 1 to 5 years after menopause. For 12 months they took 360 mcg of MK-7 a day as natto capsules, or identical olive-oil dummies. Bone density was measured at four sites. Blood markers of bone turnover and osteocalcin were also measured. Bone loss did not differ between the groups at any site. Undercarboxylated osteocalcin fell and carboxylated osteocalcin rose with MK-7. Source: PubMed abstract (PMID 19937427). Funding: grants from the Norwegian Osteoporosis Association and Northern Norway Regional Health Authorities. NATURAL provided the capsules.
325 women took 45 mg MK-4 or dummy capsules for 3 years; hip strength indices differed, bone density did not.
Trial · randomized: 161 MK-4, 164 dummy capsules; 133 and 124 finished · 3 years · maker-funded
Knapen et al., 2007
Terms and sources
- 325 women
- Apparently healthy Dutch women aged 55–75, at least 2 years after menopause. Women with low bone density (T-score below −2.5), bone conditions or anticoagulant use were excluded. 161 were assigned MK-4 and 164 dummy capsules.
- 45 mg MK-4
- Menatetrenone from Eisai, 3 capsules of 15 mg a day after meals. NIH calls 45 mg of MK-4 "a pharmacological dose" used in Japan and other parts of Asia.
- 3 years
- A later report on 164 of these women (Knapen 2012) compared body weight only within each group.
- hip strength indices differed
- Three femoral neck strength indices were significantly higher with MK-4 than with dummy capsules. They are calculated from bone density, neck width and hip axis length. Femoral neck bone mineral content fell less and femoral neck width rose with MK-4. ucOC fell and carboxylated osteocalcin rose. Total osteocalcin and bone-specific alkaline phosphatase were also higher with MK-4. Bone breakdown markers did not differ.
- bone density did not
- No difference in bone density (DXA) at the femoral neck, total hip or lumbar spine. 16 of 161 women with MK-4 and 15 of 164 with dummy capsules reported negative effects. Total complaints did not differ.
- maker-funded
- Eisai supplied the menatetrenone and an unrestricted research fund (Acknowledgement).
Study · Free full text · about 25 min to read
Our estimate at about 200 words a minute, from the PMC full text.
Study summary
325 apparently healthy Dutch women aged 55 to 75 took part, at least 2 years after menopause. They took 45 mg of MK-4 a day, as three 15 mg capsules, or dummy capsules for 3 years. 161 were assigned MK-4 and 164 dummy capsules. Bone density by DXA did not differ. Femoral neck bone mineral content fell less and femoral neck width rose with MK-4. Three calculated hip strength indices were higher with MK-4. ucOC fell. Side effects were similar. Source: PMC full text (PMID 17287908). Eisai supplied the menatetrenone and an unrestricted research fund.
244 women took 180 mcg MK-7 or dummy capsules for 3 years; bone loss differed at 2 of 3 sites.
Trial · randomized: 120 MK-7, 124 dummy capsules (from a second report of this trial) · 3 years · industry-funded
Knapen et al., 2013
Terms and sources
- 244 women
- Healthy Dutch women after menopause. A second report of the same trial (Knapen 2015) gives 120 assigned MK-7 and 124 dummy capsules.
- 180 mcg MK-7
- Capsules. The second report names the product MenaQ7.
- 3 years
- Second reports of this trial: Knapen 2015 reports that two artery-stiffness measures fell over 3 years with MK-7. Its abstract gives no comparison with dummy capsules for them. In Knapen 2015, dp-ucMGP was 50% lower than with dummy capsules; inflammation markers did not differ. Knapen 2017 found no difference in body composition in the whole group.
- bone loss differed at 2 of 3 sites
- The age-related fall in bone density and content was significantly smaller with MK-7 at the lumbar spine and femoral neck. The total hip did not differ. Calculated bone strength also differed, and loss of vertebral height (lower thoracic spine, mid-site) was smaller with MK-7. The ucOC:cOC ratio fell.
- industry-funded
- Funded by Nattopharma ASA (Acknowledgments). We could not read Methods, so we do not know who made the capsules.
Study · Abstract only · about 2 min to read
Abstract only. Our estimate at about 200 words a minute, from the PubMed abstract.
Study summary
244 healthy Dutch women after menopause took 180 mcg of MK-7 a day or dummy capsules for 3 years. Bone density and content were measured each year at the lumbar spine, total hip and femoral neck. Calculated bone strength, vertebral height and osteocalcin were also measured. The fall in bone density was smaller with MK-7 at the lumbar spine and femoral neck. The total hip did not differ. Calculated bone strength and vertebral height also differed. Source: PubMed abstract (PMID 23525894). Nattopharma ASA funded the study.
311 adults took K2, some with calcium and D, or dummy pills; 90 mcg: women lost less bone, men not.
Trial · 311 randomized into 4 groups, one of them with calcium and vitamin D; group sizes not in the abstract · 1 year
Zhang et al., 2020
Terms and sources
- 311 adults
- Men and women after menopause, aged 50–75, living in the community in China. 4 groups: 50 mcg, 90 mcg, 90 mcg with calcium 500 mg and vitamin D 10 mcg, or dummy pills. The abstract does not give group sizes or exclusions.
- K2
- The abstract does not name the form. Doses were 50 or 90 mcg a day.
- women lost less bone
- In women, femoral neck bone loss was significantly lower in both 90 mcg groups than with dummy pills (p = 0.006). One of them also took calcium and vitamin D. The abstract does not report the 50 mcg group on this measure. The ratio of carboxylated to undercarboxylated osteocalcin rose in the vitamin K2 groups.
- men not
- No effect on bone loss in men. Adding calcium and vitamin D to 90 mcg gave no additional effect.
Study · Abstract only · about 2 min to read
Abstract only. Our estimate at about 200 words a minute, from the PubMed abstract.
Study summary
311 men and women after menopause, aged 50 to 75, took part in China. They were randomly assigned to 50 or 90 mcg of vitamin K2 a day, or dummy pills, for 1 year. A fourth group took 90 mcg with calcium and vitamin D. The abstract does not name the form of vitamin K2. In women, femoral neck bone loss was lower in both 90 mcg groups than with dummy pills. Men did not differ. Source: PubMed abstract (PMID 32060566). The paper's Funding section names a Heilongjiang Province research grant.
120 adults aged 20–69 took 100 mcg MK-7 or a dummy product for 12 weeks; ucOC fell.
Trial · randomized: 60 MK-7, 60 dummy (stratified); 115 analyzed · 12 weeks · industry author
Inaba et al., J Nutr Sci Vitaminol, 2015
Terms and sources
- 120 adults aged 20–69
- Healthy Japanese men and women not under medical treatment; 60 were allocated to each group. People with abnormal or unstable osteocalcin values at screening were excluded. This is Study 2 of the paper; Study 1, listed below, chose the dose.
- ucOC fell
- Undercarboxylated osteocalcin fell, and the ratio of carboxylated to undercarboxylated osteocalcin rose, significantly more with MK-7 than with the dummy. Clotting time (PT-INR) did not differ between groups. The paper reports no adverse effects linked to the products.
- industry author
- All three authors are from the R&D Division of J-Oil Mills, Inc. The paper states: "This study did not receive any funding."
Study · Free full text · about 23 min to read
Free full text on J-STAGE. Our estimate at about 200 words a minute, from the J-STAGE full text.
Study summary
This is the second of two trials in this report. 120 Japanese adults aged 20 to 69 took 100 mcg of MK-7 or a dummy product for 12 weeks. Blood carboxylated and undercarboxylated osteocalcin were measured. Undercarboxylated osteocalcin fell with MK-7 compared with the dummy. The ratio of carboxylated to undercarboxylated osteocalcin rose. Source: J-STAGE full text (PMID 26875489). All three authors work at J-Oil Mills, Inc.; the paper reports no funding.
71 adults finished 12 weeks of 240 mcg MK-7 or dummy tablets; blood MK-7 rose, exercise recovery did not differ.
Trial · 80 enrolled, 75 completed baseline tests, 71 finished; the text we read does not give the number randomized to each group · 12 weeks · maker-funded
Lithgow et al., Med Sci Sports Exerc, 2026
Terms and sources
- 71 adults
- Healthy adults aged 18–40 and 65+ in Glasgow who did little hard exercise. 35 young and 36 older adults finished. People with listed conditions, smokers and anyone taking vitamin K antagonists were excluded.
- 240 mcg MK-7
- One tablet a day with lunch or dinner (K2VITAL). The dummy was a cellulose tablet that looked and tasted the same.
- exercise recovery did not differ
- Strength, sit-to-stand time, soreness and inflammation markers up to 72 hours after exercise: no supplement-by-time differences. Blood MK-7 rose with MK-7. In older adults only, muscle-signal measures (EMD, RMS), creatine kinase and IL-6 differed by group. The authors call these exploratory. Slower sit-to-stand time and less soreness in the MK-7 group were overall group effects, not changes over time. Older adults also had lower dp-ucMGP at 12 weeks with MK-7.
- maker-funded
- Kappa Bioscience AS funded the study and provided the tablets. The paper calls it the manufacturer. It had no role in data collection or analysis.
Study · Free full text · about 25 min to read
Our estimate at about 200 words a minute, from the PMC full text.
Study summary
Healthy adults aged 18 to 40 and 65 and over took part. They did little resistance exercise. They took 240 mcg of MK-7 or a dummy tablet a day for 12 weeks. 80 enrolled and 71 finished. Before and after, they did one bout of leg and chest exercise. Strength, sit-to-stand time, soreness and blood markers were measured over 72 hours. Recovery did not differ between groups. Blood MK-7 rose. Some measures in older adults differed by group. Source: PMC full text (PMID 41843412). Kappa Bioscience funded the study and provided the tablets.
60 adults took 180 or 360 mcg MK-7 or a dummy product; dp-ucMGP fell, other markers did not differ.
Trial · randomized to 3 groups; group sizes not in the abstract · 12 weeks
Dalmeijer et al., 2012
Terms and sources
- 60 adults
- Dutch men and women aged 40–65. The abstract does not state health criteria or group sizes.
- dp-ucMGP fell
- Inactive matrix Gla protein fell by 31% with 180 mcg and 46% with 360 mcg (p < 0.001). It did not change with the dummy. The ucOC:cOC ratio fell by 60% and 74%.
- other markers did not differ
- Two other forms of matrix Gla protein and other risk markers did not differ between the groups.
Study · Abstract only · about 2 min to read
Abstract only. Our estimate at about 200 words a minute, from the PubMed abstract.
Study summary
60 Dutch men and women aged 40 to 65 took part. They took 180 or 360 mcg of MK-7 a day or a dummy product for 12 weeks. Forms of matrix Gla protein, the osteocalcin ratio and other risk markers were measured at 0, 4 and 12 weeks. Inactive matrix Gla protein (dp-ucMGP) fell with both doses. It did not change with the dummy. Two other forms of the protein and other risk markers did not differ. Source: PubMed abstract (PMID 23062766). Europe PMC lists the Netherlands Heart Foundation as the funder.
60 women took MK-7 or a dummy; carboxylation ratio higher at 100–200 mcg; cOC, ucOC levels did not differ.
Trial · allocated to 4 groups of 15 by stratified randomization; 57 analyzed · 4 weeks · industry author
Inaba et al., J Nutr Sci Vitaminol, 2015
Terms and sources
- 60 women
- Japanese women aged 50–69 after menopause. They ate a controlled diet with the Japanese recommended vitamin K intake. 15 women were allocated to each dose group: 0, 50, 100 or 200 mcg. This is Study 1 of the paper.
- a dummy
- MK-7 was dissolved in oil and processed into 20 g of mayonnaise (Knorr Foods). The 0 mcg mayonnaise was identical in appearance, texture and taste.
- carboxylation ratio higher at 100–200 mcg
- The ratio of carboxylated to undercarboxylated osteocalcin was measured. Its change from baseline was significantly higher at 100 and 200 mcg than at 0 mcg. The paper reports no significant difference at 50 mcg. In the 0 mcg group, the ratio fell from baseline.
- cOC, ucOC levels did not differ
- Concentrations of carboxylated and undercarboxylated osteocalcin did not differ significantly among the groups. Within groups, ucOC rose from baseline at 0 mcg and fell at 200 mcg. The paper reports no adverse effects linked to the products.
- industry author
- All three authors are from the R&D Division of J-Oil Mills, Inc. The paper states: "This study did not receive any funding." The MK-7 was dissolved in oil from J-Oil Mills.
Study · Free full text · about 23 min to read
Free full text on J-STAGE. Our estimate at about 200 words a minute, from the J-STAGE full text.
Study summary
This is the first of two trials in this report. 60 Japanese women aged 50 to 69 after menopause ate a controlled diet. They took 0, 50, 100 or 200 mcg of MK-7 a day for 4 weeks. Blood carboxylated and undercarboxylated osteocalcin were measured. Their ratio fell from baseline at 0 mcg. Its change was higher at 100 and 200 mcg than at 0 mcg. Concentrations of the two forms did not differ between groups. Source: J-STAGE full text (PMID 26875489). All three authors work at J-Oil Mills, Inc.; the paper reports no funding.
48 women took 1.5 mg MK-4 or a dummy product for 12 months; ucOC was lower than with the dummy.
Trial · randomized: 24 MK-4, 24 dummy · 12 months · industry co-funded
Koitaya et al., J Bone Miner Metab, 2014
Terms and sources
- 48 women
- Japanese women aged 50–65 after menopause; 24 were assigned MK-4 and 24 the dummy. The paper aimed to test healthy women. ucOC was high at the start in both groups.
- ucOC was lower
- Lower with MK-4 than with the dummy at 6 and 12 months. Forearm bone density and pentosidine were compared only within each group. Forearm density fell between 6 and 12 months with the dummy, not with MK-4.
- industry co-funded
- Funded by a grant from Japan's National Institute of Health and Nutrition and by Kyowa Hakko Bio (Acknowledgments). Four authors work at Kyowa Hakko Bio. The authors declare no conflicts of interest. We could not read Methods, so we do not know who made the product.
Study · Abstract only · about 2 min to read
Abstract only. Our estimate at about 200 words a minute, from the PubMed abstract.
Study summary
48 Japanese women aged 50 to 65 after menopause took part. They took 1.5 mg of MK-4 a day or a dummy product for 12 months; 24 were in each group. Bone turnover markers, ucOC, pentosidine and forearm bone density were measured at 0, 6 and 12 months. ucOC was lower with MK-4 than with the dummy at 6 and 12 months. Forearm density was compared only within each group. Source: PubMed abstract (PMID 23702931). Funding: a government institute grant and Kyowa Hakko Bio.
42 adults took 10–360 mcg MK-7 or dummy capsules; carboxylation rose at higher doses; thrombin generation did not change.
Trial · randomized to 7 groups of 6: dummy capsules or 10, 20, 45, 90, 180 or 360 mcg · 12 weeks · maker-funded
Theuwissen et al., Br J Nutr, 2012
Terms and sources
- 42 adults
- Healthy Dutch men and women aged 18–45. Seven groups: dummy capsules or 10, 20, 45, 90, 180 or 360 mcg of MK-7. Six people per group, for 12 weeks (Methods).
- carboxylation rose at higher doses
- For statistics, the authors pooled the groups into dummy, doses below and doses around the EU recommended daily amount. Osteocalcin and matrix Gla protein carboxylation rose at doses around that amount. A later report on stored samples (Knapen 2012) found no link between vitamin K status and adiponectin.
- thrombin generation did not change
- Calibrated thrombin generation tests: the abstract reports no adverse effects.
- maker-funded
- Nattopharma ASA funded the study (Acknowledgements). Methods say NattoPharma ASA produced the MenaQ7 capsules, including the dummy capsules. The paper reports no author conflicts of interest.
Study · Abstract only · about 2 min to read
Abstract only. Our estimate at about 200 words a minute, from the PubMed abstract.
Study summary
42 healthy Dutch adults aged 18 to 45 took part. They were randomly assigned to dummy capsules or one of six MK-7 doses, 10 to 360 mcg. Each group had 6 people and took capsules for 12 weeks. Osteocalcin, matrix Gla protein and thrombin generation were measured. With dose groups combined, carboxylation of both proteins rose at doses around the EU recommended amount. Thrombin generation showed no adverse effects. Source: PubMed abstract and the journal page (PMID 22289649). Nattopharma ASA funded the study and produced the capsules.